U.S. Diagnostics Reimbursement and Commercial Adoption

In U.S. diagnostics, reimbursement is not a back-office detail — it is the commercial gate that determines whether a test gets ordered, adopted, and sustained. A diagnostic product with strong clinical performance and a clear unmet need can still fail commercially if the reimbursement pathway is unclear, contested, or economically unworkable for the customer. For international companies entering the U.S. market, understanding reimbursement before launch is the difference between a product that scales and one that stalls.

U.S. diagnostics reimbursement is shaped by several interconnected layers. Medicare coverage decisions — through national and local coverage determinations — set reference points that private payers frequently follow. The Clinical Laboratory Fee Schedule and the Physician Fee Schedule establish the payment rates that determine what a laboratory or provider actually receives for performing a test. Private payer policies vary by plan, region, and site of care, and adoption often lags Medicare by months or years. A test that relies on a new code, a gap in coverage, or a case-by-case appeals process faces a slower, more capital-intensive path to utilization than one that fits an established, covered category.

Site-of-care economics compound the challenge. A test that is economically viable in a high-volume reference laboratory may be unworkable in a hospital setting, where the cost structure, decision-maker, and competitive alternatives are different. Pricing that assumes one site of care can fail in another. Usage frequency, payer mix, and the customer's ability to absorb upfront instrument or infrastructure costs all shape whether adoption is sustainable — not just possible.

Reimbursement planning belongs at the start of commercialization, alongside customer segmentation and pricing — not after the product is built and the channel is selected. When a company understands the reimbursement pathway early, it can shape the evidence package, the pricing model, and the target customer around a path that actually pays. Vernon Row helps diagnostics companies map that pathway before significant capital is committed, so the commercial model is built on reimbursement realities rather than assumptions.